SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as community members discuss its potential link to ExxonMobil's carbon capture technology for powering data centers, sparking optimism for the stock's future. The stock's recent surge in trading volume and price has investors comparing it to sector peer Bloom Energy, while analyzing options activity and potential news catalysts. Despite past performance concerns, some believe FuelCell is now well-positioned to capitalize on increasing demand for clean and reliable energy solutions.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to a potential bidding war between Novo Nordisk and Pfizer to acquire the company and its obesity drug pipeline, with Pfizer even filing a lawsuit related to the offers. Community members are discussing whether Pfizer will increase its bid or if another company like Eli Lilly could enter the competition. The surge in interest is also fueled by recent data, though some debate the drug's efficacy and side effect profile compared to competitors.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWXT is trending as the community discusses its strong position in the nuclear sector and potential benefits from increased demand for nuclear energy, especially with the rise of AI and data centers. Some investors are drawing comparisons between BWXT and Nvidia, suggesting that BWXT could become a key player in the nuclear energy space similar to Nvidia's role in AI. High institutional ownership and government contracts are also being noted as potential drivers for growth.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending as the community discusses its potential role in AI-driven identity verification, especially following news of partnerships and treasury initiatives centered around WLD. Community members are weighing the long-term outlook and speculating on integration with projects like OpenAI, while some are closely monitoring price movements and key levels. The broader conversation includes discussion around the need for proof-of-humanity solutions in the face of increasing AI development.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a significant price increase and higher than average trading volume, sparking community discussion about potential catalysts. Some speculate on a possible buyout, while others express concerns about past stock performance and the impact of opinions from individuals in the FDA. Upcoming presentations of new data on LUPKYNIS may also be influencing the stock's movement.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy ($PRO) is trending due to discussions around potential pumps and dumps, with community members actively debating price movements and trading strategies. The coin's association with Real World Assets (RWAs) and real estate transactions is also a prominent talking point. Some traders are expressing frustration with price volatility, while others remain bullish on its long-term potential.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN) is trending amidst community debate about its price action and potential. Some investors express frustration over recent declines and accuse the coin of being a "shitcoin" or "scam", while others remain optimistic, citing upcoming developments like the Goliath mainnet launch and staking rewards. Technical analysis and comparisons to other cryptocurrencies are also being discussed.

Tidal Trust II - YieldMax Dorsey Wright Featured 5 Income ETF

YieldMax Dorsey Wright Featured 5 Income ETF

Investors are closely watching $FEAT, a YieldMax ETF, as it transitions to weekly distributions, sparking discussions around payout estimates and the impact on cash flow. The community is also focused on the ETF's top holdings and its actively managed options strategies, particularly after YieldMax announced changes to their distribution schedule. Some are expressing concerns about the ETF's performance since inception, while others remain optimistic about its high yield potential.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is trending as gold prices reach all-time highs amid global economic uncertainty and US-China trade tensions, although the ETF experienced a significant pullback recently. The community debates whether this is a buying opportunity or the start of a larger correction, with some noting overbought conditions and potential for a short-term decline. Many analysts see long-term potential due to strong earnings expectations and central bank demand for gold, though broader market sentiment and upcoming economic data releases add to the uncertainty.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio is trending following strong Q3 earnings and a raised 2025 revenue outlook, driving positive sentiment among investors. The community is focused on price target increases from analysts and the potential impact of AI on Twilio's growth. Discussions also involve Twilio's market position and whether the company is undervalued, especially compared to its peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?

Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research 10x Genomics Launches the Next Generation of Chromium Flex to Empower...

Cathie Wood pours $19.2 million on biotech stock, trims favorite

Love her or roll your eyes, Cathie Wood's bets are virtually impossible for investors to miss.With clear theses and gutsy bets early on, the ARK Invest boss is willing to flip the script when the...

10x Genomics (TXG) Moves 11.1% Higher: Will This Strength Last?

10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>10x Genomics is partnering with Anthropic to integrate its single cell and spatial biology analysis tools into Claude for Life Sciences.</li><li>Researchers can now perform advanced analytical tasks through conversational queries in plain English, reducing the need for computational expertise.&nbsp;</li></ul>10x Genomics Inc. (TXG) on Monday announced partnership with artificial intelligence company Anthropic to make its single-cell and spatial biology analysis tools accessible through natural language using Claude, Anthropic’s AI platform.&nbsp;The integration will connect 10x Genomics’ Cloud Analysis platform to Anthropic’s Claude for Life Sciences using the Model Context Protocol (MCP), a framework designed to link AI systems with specialized research tools.Following the collaboration,&nbsp;10x Genomics’ stock traded over 9% higher on Monday afternoon. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘normal’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:937/99;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_20_133011_png_50666f7d93.webp" alt="TXGs Sentiment Meter and Message Volume as of 01:20 p.m. ET on Oct. 20, 2025 | Source: Stocktwits" width="937" height="99"><figcaption>TXGs Sentiment Meter and Message Volume as of 01:20 p.m. ET on Oct. 20, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">How Will Claude Help Researchers?&nbsp;</h2>Until now, accessing 10x’s genomic analysis tools often required writing command-line code and working with powerful computing infrastructure. The Claude integration allows researchers to ask questions in plain English and receive results through the AI interface.&nbsp;<blockquote>"Through Claude for Life Sciences, tasks that traditionally required computational expertise, can now happen through natural conversation.”-Eric Kauderer-Abrams, Head of Life Sciences and Biology, Anthropic</blockquote>&nbsp;“When we enable human expertise and AI to work together across the scientific process—from hypothesis generation to data interpretation to publication—we can accelerate discovery and progress against disease," he said.<h2 class="st-heading-2">10x Genomics’ Motive</h2>10x Genomics helps academic, clinical, and biopharma researchers study complex biological systems with tools to support discoveries in fields like oncology, immunology, and neuroscience.The company is scheduled to report the third-quarter (Q3) earnings on November 6 and expects revenue to be in the range of $140 million to $144 million, against the analysts’ consensus estimate of $142.5 million, according to Fidcal AI data.&nbsp;10x Genomics’ stock has lost over 9% in 2025 and over 15% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-hits-fresh-all-time-highs-on-i-phone-17-demand-momentum/ch66TekR3pb">Apple Stock Hits Fresh All-Time Highs On iPhone 17 Demand Momentum</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, 10x Genomics logo of an US biotechnology company is seen on a smartphone screen.

10x Genomics Partners With Anthropic To Bring AI Tools For Researchers

10x Genomics is partnering with Anthropic to integrate its single cell and spatial biology analysis tools into Claude for Life Sciences.

Equity

Zacks.com featured highlights include Red Robin Gourmet Burgers, 10x Genomics, Norwegian Cruise Line, Electromed and Analog Devices

Zacks spotlights five efficient stocks  Red Robin, 10x Genomics, Norwegian Cruise Line, Electromed, and Analog Devices that excel in turning assets and operations into profits.

PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations

PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.

Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?

TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.

5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns

From Red Robin to Analog Devices, these five high-efficiency stocks stand out for their strong ratios and surprise earnings potential.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

10x Genomics Inc - Ordinary Shares - Class A

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.29	--	--	N/A
Q2 '25	-$0.37	$0.28	175.35%	BEAT
Q1 '25	-$0.47	-$0.28	40.09%	BEAT
Q4 '24	-$0.30	-$0.40	-33.66%	MISSED
Q3 '24	-$0.34	-$0.30	11.54%	BEAT

TXG
10x Genomics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TXG News

TXG10x Genomics Inc - Ordinary Shares - Class A